RxDoctor Payments DataLook up a doctor →

Christen Kutz, PA

Medical · Colorado Springs, CONPI 1629138813

Payments from drug & device makers

$2,389,560in general payments, 2019–2025

Across 1,974 payments — averaging $1210.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$530K
  • E.r. Squibb & Sons, L.L.C.$429K
  • TG Therapeutics, Inc.$333K
  • Novartis$266K
  • EMD Serono, Inc.$149K
  • Biogen$131K
  • plus $551K from 54 others
$25,590in research payments, 2019–2025

Across 5 payments — averaging $5117.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • TG Therapeutics, Inc.$13K
  • Neurocrine Biosciences, Inc.$7K
  • Eli Lilly$6K

What the payments were for

  • Consulting fees$99,21716%
  • Speaking & faculty fees$412,40568%
  • Travel & lodging$40,3567%
  • Food & beverage$40,1937%
  • Education$17,5143%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly28$529,856
E.r. Squibb & Sons, L.L.C.58$429,394
TG Therapeutics, Inc.138$332,606
Novartis54$266,242
EMD Serono, Inc.231$149,216
Biogen247$130,702
H. Lundbeck A S15$100,527
Takeda Pharmaceuticals U.S.A., Inc.9$75,877
AstraZeneca(2 entities)136$60,819
Teva Pharmaceuticals USA, Inc.50$55,998
AbbVie(2 entities)196$44,976
Vanda Pharmaceuticals Inc.49$35,365
Integrative Research Laboratories Sweden AB8$30,074
Sanofi72$29,689
Roche Products Limited35$27,666
Bristol Myers Squibb88$24,666
Amgen(2 entities)63$21,791
Johnson & Johnson(2 entities)38$19,815
Axsome Therapeutics, Inc.11$5,835
Lilly USA, LLC45$5,425
Neurocrine Biosciences, Inc.19$2,469
Janssen Scientific Affairs, LLC5$1,214
UCB, Inc.29$926
Pfizer46$798
Eisai Inc.23$703
Merz Pharmaceuticals, LLC18$497
Neurelis, Inc.15$446
Mallinckrodt Hospital Products Inc.17$412
SK Life Science, Inc.16$411
Jazz Pharmaceuticals Inc.15$408
Argenx US, Inc.17$380
Abbott10$359
Acadia Pharmaceuticals Inc14$304
Acorda Therapeutics, Inc8$286
Genentech USA, Inc.11$275
Regeneron1$270
Biohaven Pharmaceutical Holding Company Ltd.14$256
Harmony Biosciences LLC7$225
Biohaven Pharmaceuticals, Inc.18$217
Tanabe Pharma America, Inc.10$202
ANI Pharmaceuticals, Inc.8$191
Ipsen Biopharmaceuticals, Inc8$168
Livanova USA, Inc.7$150
Lundbeck LLC7$149
CSL Behring4$110
GRT US Holding, Inc.6$95
Octapharma USA, Inc.4$92
Sunovion Pharmaceuticals Inc.4$82
Amneal Pharmaceuticals LLC3$78
Otsuka America Pharmaceutical, Inc.4$78
MDD US Operations, LLC3$71
Kyowa Kirin, Inc.3$65
Banner Life Sciences, LLC3$59
Alnylam Pharmaceuticals Inc.3$57
Insightec,inc2$48
Greenwich Biosciences, Inc.2$46
Collegium Pharmaceutical, Inc.2$46
Boston Scientific2$44
Ultragenyx Pharmaceutical Inc.2$42
Philips North America LLC1$42

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,389,560 in reported general payments places this provider in the 95th percentile of 766 medical providers in Colorado.

See all medical providers in Colorado

Medicare billing

Part B allowed, 2024
$183,790
Medicare patients
284
Services billed
6,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate25$234,405
AubagioTeriflunomide22$202,493
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5024$126,187
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5015$123,610
UbrelvyUbrogepant89$96,544
NuplazidPimavanserin Tartrate18$89,669
Nurtec OdtRimegepant Sulfate52$73,554
QuliptaAtogepant51$58,850
Dimethyl Fumarate29$44,214
Aimovig AutoinjectorErenumab-Aooe42$38,227
InbrijaLevodopa18$22,495
ValtocoDiazepam13$19,663
Emgality PenGalcanezumab-Gnlm23$17,383
SavellaMilnacipran Hcl15$13,920
RytaryCarbidopa/Levodopa15$11,675

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$130,702$234,40525 claims
SanofiAubagio$29,689$202,49322 claims
AbbVieUbrelvy, Qulipta, Savella$44,976$169,314155 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$75,877$123,61015 claims
Acadia Pharmaceuticals IncNuplazid$304$89,66918 claims
PfizerNurtec Odt$798$73,55452 claims
Acorda Therapeutics, IncInbrija$286$22,49518 claims
Neurelis, Inc.Valtoco$446$19,66313 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$78$13,46833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 766 medical providers in Colorado.

Other medical in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →